Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

American Journal of Hematology

Volumn 62, Issue 4, 1999, Pages 247-250

  Yang, Honghao ^a   Rosove, Michael H ^a   Figlin, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Chronic lymphocytic lymphoma; IDEC C2B8; Immunotherapy; Lymphoproliferative disorder; Non Hodgkin's lymphoma; Rituximab; Tumor lysis syndrome

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER IMMUNOTHERAPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; DRUG INDUCED DISEASE; FEMALE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TREATMENT INDICATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FATAL OUTCOME; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, NON-HODGKIN; MALE; TUMOR LYSIS SYNDROME;

EID: 0032736341     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199912)62:4<247::AID-AJH9>3.0.CO;2-T     Document Type: Article

References (19)

1. Anderson DR, Grillo-Lopez A, Varns C, et al. Target anti-cancer therapy using rituximab, a chimeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans 1997;25:705-708.
2. Stashenko P, Nadler LM, Hardy R, Schlossmann SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678-1684.
3. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-445.
4. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Practice 1998;6:195-197.
5. Prescribing Information, 1997. IDEC Pharmaceutics Corporation and Genentech.
6. Jensen M, Winker U, Manzke O, Diehl V, Engert A. Rapid tumor lysis in a patient with B-cell chronic lymphocyte leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998;77:89-91.
7. Shipp MA, Harrington DR, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphomas treated with n-BACOD or m-BACOD. Ann Intern Med 1986;104:757.
8. Wyndham HW, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD, Chabner BA. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1573-1582.
9. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood 1988;71:117-122.
10. Tsokos GC, Balow JE, Spiegel RJ, Magrath IT. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) 1981;60:218-229.
11. Cohen LG, Balow JE, Macgrath IT, Poplack DG, Ziegler JL. Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med 1980;68:486-491.
12. Zusman J, Brown DM, Nesbit ME. Hyperphosphatemia, hyperphosphaturia and hypocalcemia in acute lymphoblastic leukemia. N Engl J Med 1973;289:1335.
13. Vogelzang NJ, Nelimark RA, Nath KA. Tumor lysis syndrome after induction chemotherapy of small-cell bronchogenic carcinoma. JAMA 1983;249:513-514.
14. Stark ME, Dyler MCD, Coonley CJ. Fatal acute tumor lysis syndrome with metastatic breast carcinoma. Cancer 1987;60:762-764.
15. Fer MF, Bottino GC, Sherwin SA, Hainsworth JD, Abrams PG, Foon KA, Oldham RK. Atypical tumor lysis syndrome in a patient with T cell lymphoma treated with recombinant leukocyte interferon. Ame J Med 1984;77:953-956.
16. Gold JE, Malamud SC, LaRosa F, Osband ME. Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma. Am J Hematol 1993;44:42-47.
17. Minasian LM, Szatrowski TP, Rosenblum M, Steffens T, Morrison ME, Chapman PB, Williams L, Nathan CF, Houghton AN. Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-a and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. Blood 1994;83:56-64.
18. Arrambide K, Toto RD. Tumor lysis syndrome. Semin Nephrol 1993; 13:273-280.
19. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91:1644-1652.